Novartis | NOVN - Ordinary Share Capital


Novartis reported $1.9B in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Alcon AG USD 487.4M 0 Jun/2026
Almirall EUR 214.79M 0 Dec/2025
Amgen USD 541M 1000K Jun/2026
AstraZeneca USD 1.55B 44K Jun/2026
Autolus Therapeutics Ltd USD 266.14M 0 Mar/2026
Bayer EUR 982.42M 0 Jun/2026
Biogen USD 146.7M 200K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Fresenius EUR 563.24M 0 Jun/2026
Fresenius Medical Care EUR 266.11M 3.98M Jun/2026
Genmab DKK 61.44M 181K Jun/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
GRIFOLS EUR 680.58M 6K Jun/2026
Hikma Pharmaceutical USD 221.89M 181.89M Dec/2025
J&J USD 2.41B 1.35M Mar/2026
Lakefront Biotherapeutics EUR 65.66M 242K Jun/2026
Lonza CHF 68.64M 0 Dec/2025
Merck EUR 434.78M 0 Jun/2026
Merck USD 2.47B 4.93M Mar/2026
Novartis USD 1.9B 7.38M Jun/2026
Novartis USD 1.91B 60K Mar/2026
Novo Nordisk DKK 4.43B 13.25M Jun/2026
Orion EUR 140.87M 0 Jun/2026
Pfizer USD 5.7B 0 Jun/2026
Philips EUR 952.02M 729K Mar/2026
Recordati EUR 204.81M 1.38M Jun/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sanofi EUR 1.21B 8.25M Mar/2026
UCB EUR 190.36M 365.15K Dec/2025